Oleoyl-estrone

Identification

Name
Oleoyl-estrone
Accession Number
DB04870
Type
Small Molecule
Groups
Investigational
Description

Oleoyl-estrone (OE) is a fatty acid ester of estrone. It is a naturally circulating hormone in animals including humans. It was first reported in 1996 to cause a body fat loss effect in rats in the International Journal of Obesity and Related Metabolic Disorders. The animal research has all been conducted by the Nitrogen-Obesity Research Group of the University of Barcelona. The compound was found to potently induce body-fat loss while preserving protein stores in animals which is the ultimate goal of an anti-obesity agent as body protein loss is an undesired but inevitable (to some degree) side effect of fat loss via calorie restriction. [Wikipedia]

Structure
Thumb
Synonyms
  • Estrone 3-oleate
  • Estrone monooleate
  • Estrone oleic acid ester
  • OE
  • Oleoyl estrone
  • Oleoylestrone
External IDs
MP-101
Categories
UNII
64R56KMG1Z
CAS number
180003-17-2
Weight
Average: 534.8122
Monoisotopic: 534.407295594
Chemical Formula
C36H54O3
InChI Key
IMIPDPVHGGHVNH-YWVHRCQQSA-N
InChI
InChI=1S/C36H54O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-35(38)39-29-20-22-30-28(27-29)19-21-32-31(30)25-26-36(2)33(32)23-24-34(36)37/h10-11,20,22,27,31-33H,3-9,12-19,21,23-26H2,1-2H3/b11-10-/t31-,32-,33+,36+/m1/s1
IUPAC Name
(1S,10R,11S,15S)-15-methyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-5-yl (9Z)-octadec-9-enoate
SMILES
[H][[email protected]@]12CCC(=O)[[email protected]@]1(C)CC[[email protected]]1([H])C3=C(CC[[email protected]@]21[H])C=C(OC(=O)CCCCCCC\C=C/CCCCCCCC)C=C3

Pharmacology

Indication

For the treatment of obesity.

Structured Indications
Not Available
Pharmacodynamics

Oleoyl-estrone is a fatty acid ester of estrone, and may be directly involved in the control of body weight (PMID: 8782737).

Mechanism of action

Based on extensive preclinical studies, it is believed that oleoyl-estrone (OE) works by a dual mechanism of action. Centrally, OE appears to act at the brain's hypothalamus, resetting the body's ponderostat, the “food control center” in the brain that detects and integrates signals that control both appetite and metabolic behavior. Peripherally, OE also causes reduced storage of fat in “white fat” tissue and allows skeletal muscle to use fat as an alternate energy source.

Absorption

Orally available

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Oleoyl-estrone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Oleoyl-estrone.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Oleoyl-estrone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Oleoyl-estrone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Oleoyl-estrone.Approved, Withdrawn
AldesleukinOleoyl-estrone may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Oleoyl-estrone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Oleoyl-estrone.Experimental
AloglutamolThe bioavailability of Oleoyl-estrone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Oleoyl-estrone.Experimental
AluminiumThe bioavailability of Oleoyl-estrone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Oleoyl-estrone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Oleoyl-estrone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Oleoyl-estrone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Oleoyl-estrone.Approved
AmiodaroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BOleoyl-estrone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Oleoyl-estrone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Oleoyl-estrone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Oleoyl-estrone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Oleoyl-estrone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Oleoyl-estrone.Approved, Investigational
AprepitantThe serum concentration of Oleoyl-estrone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Oleoyl-estrone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Oleoyl-estrone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Oleoyl-estrone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oleoyl-estrone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Oleoyl-estrone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Oleoyl-estrone.Experimental
BendroflumethiazideOleoyl-estrone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Oleoyl-estrone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Oleoyl-estrone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Oleoyl-estrone.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Oleoyl-estrone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Oleoyl-estrone.Experimental
Bismuth SubcitrateThe bioavailability of Oleoyl-estrone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Oleoyl-estrone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Oleoyl-estrone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oleoyl-estrone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Oleoyl-estrone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Oleoyl-estrone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Oleoyl-estrone.Experimental
BumetanideOleoyl-estrone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Oleoyl-estrone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Oleoyl-estrone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Oleoyl-estrone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideOleoyl-estrone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Oleoyl-estrone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Oleoyl-estrone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oleoyl-estrone.Approved, Investigational
CeritinibOleoyl-estrone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oleoyl-estrone.Approved, Vet Approved
ChlorothiazideOleoyl-estrone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneOleoyl-estrone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Oleoyl-estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Oleoyl-estrone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Oleoyl-estrone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Oleoyl-estrone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Oleoyl-estrone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Oleoyl-estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Oleoyl-estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Oleoyl-estrone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Oleoyl-estrone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Oleoyl-estrone.Investigational
CyclopenthiazideOleoyl-estrone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Oleoyl-estrone.Investigational
DaidzeinThe serum concentration of Oleoyl-estrone can be increased when it is combined with Daidzein.Experimental
DanazolOleoyl-estrone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Oleoyl-estrone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Oleoyl-estrone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oleoyl-estrone.Approved, Vet Approved
DienestrolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Oleoyl-estrone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oleoyl-estrone.Approved
DihydrotestosteroneOleoyl-estrone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Oleoyl-estrone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Oleoyl-estrone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Oleoyl-estrone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Oleoyl-estrone.Approved
EquolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Oleoyl-estrone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Estrone.Approved
Etacrynic acidOleoyl-estrone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Oleoyl-estrone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Oleoyl-estrone.Experimental
Ethinyl EstradiolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Oleoyl-estrone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Oleoyl-estrone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Oleoyl-estrone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Oleoyl-estrone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Oleoyl-estrone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Oleoyl-estrone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Oleoyl-estrone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oleoyl-estrone.Approved
FenthionThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Oleoyl-estrone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Oleoyl-estrone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Oleoyl-estrone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Oleoyl-estrone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Oleoyl-estrone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Oleoyl-estrone.Experimental
FluoxymesteroneOleoyl-estrone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oleoyl-estrone.Approved, Investigational
FosaprepitantThe serum concentration of Oleoyl-estrone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideOleoyl-estrone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Oleoyl-estrone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with GI-5005.Investigational
GLPG-0492Oleoyl-estrone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Oleoyl-estrone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Oleoyl-estrone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Oleoyl-estrone.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Oleoyl-estrone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Oleoyl-estrone.Approved, Investigational
HydrochlorothiazideOleoyl-estrone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideOleoyl-estrone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Oleoyl-estrone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Oleoyl-estrone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Oleoyl-estrone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Oleoyl-estrone.Approved
IdelalisibThe serum concentration of Oleoyl-estrone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Oleoyl-estrone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Oleoyl-estrone.Approved
IndapamideOleoyl-estrone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Oleoyl-estrone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Oleoyl-estrone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oleoyl-estrone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Oleoyl-estrone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Oleoyl-estrone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Oleoyl-estrone.Withdrawn
ItraconazoleThe serum concentration of Oleoyl-estrone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Oleoyl-estrone.Experimental
KetoconazoleThe serum concentration of Oleoyl-estrone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Oleoyl-estrone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oleoyl-estrone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Oleoyl-estrone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Oleoyl-estrone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Oleoyl-estrone.Experimental
LopinavirThe serum concentration of Oleoyl-estrone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Oleoyl-estrone.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Oleoyl-estrone.Approved, Investigational
LumacaftorThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Oleoyl-estrone.Approved, Investigational
MagaldrateThe bioavailability of Oleoyl-estrone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Oleoyl-estrone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Oleoyl-estrone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Oleoyl-estrone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oleoyl-estrone.Approved
Magnesium silicateThe bioavailability of Oleoyl-estrone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Oleoyl-estrone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oleoyl-estrone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oleoyl-estrone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oleoyl-estrone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oleoyl-estrone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Oleoyl-estrone.Approved
MesteroloneOleoyl-estrone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Oleoyl-estrone.Investigational, Withdrawn
MethallenestrilThe serum concentration of Oleoyl-estrone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideOleoyl-estrone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Oleoyl-estrone.Approved, Vet Approved
MethyltestosteroneOleoyl-estrone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Metoclopramide.Approved, Investigational
MetolazoneOleoyl-estrone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Oleoyl-estrone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Minaprine.Approved
MitotaneThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Oleoyl-estrone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Oleoyl-estrone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Oleoyl-estrone.Experimental
MoxestrolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oleoyl-estrone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oleoyl-estrone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Oleoyl-estrone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Oleoyl-estrone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Oleoyl-estrone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Nalidixic Acid.Approved, Investigational
NandroloneOleoyl-estrone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateOleoyl-estrone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Oleoyl-estrone.Approved, Vet Approved
NefazodoneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Oleoyl-estrone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Oleoyl-estrone.Approved
NevirapineThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Oleoyl-estrone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Oleoyl-estrone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Oleoyl-estrone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Oleoyl-estrone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oleoyl-estrone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oleoyl-estrone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Oleoyl-estrone.Vet Approved
OxandroloneOleoyl-estrone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Oleoyl-estrone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Oxolinic acid.Experimental
OxymetholoneOleoyl-estrone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Oleoyl-estrone.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Oleoyl-estrone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Oleoyl-estrone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Oleoyl-estrone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oleoyl-estrone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Oleoyl-estrone.Approved, Investigational
PhenytoinThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oleoyl-estrone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Pipemidic acid.Experimental
PiretanideOleoyl-estrone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Oleoyl-estrone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oleoyl-estrone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Oleoyl-estrone.Experimental
Polyestradiol phosphateThe serum concentration of Oleoyl-estrone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideOleoyl-estrone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Oleoyl-estrone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Oleoyl-estrone.Experimental, Investigational
PrimidoneThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Oleoyl-estrone.Experimental
PromestrieneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Oleoyl-estrone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Oleoyl-estrone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Oleoyl-estrone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Oleoyl-estrone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Quinestrol.Approved
QuinethazoneOleoyl-estrone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Oleoyl-estrone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oleoyl-estrone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Oleoyl-estrone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Oleoyl-estrone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oleoyl-estrone.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Oleoyl-estrone.Approved
SaquinavirThe serum concentration of Oleoyl-estrone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Oleoyl-estrone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Oleoyl-estrone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Oleoyl-estrone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Oleoyl-estrone can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Oleoyl-estrone.Investigational
St. John's WortThe serum concentration of Oleoyl-estrone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololOleoyl-estrone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oleoyl-estrone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Oleoyl-estrone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Oleoyl-estrone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Oleoyl-estrone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Oleoyl-estrone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Oleoyl-estrone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Oleoyl-estrone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Oleoyl-estrone.Approved, Withdrawn
TelithromycinThe serum concentration of Oleoyl-estrone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Oleoyl-estrone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oleoyl-estrone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Oleoyl-estrone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Oleoyl-estrone.Approved
TestosteroneOleoyl-estrone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateOleoyl-estrone may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Oleoyl-estrone.Approved
TiboloneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Oleoyl-estrone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Oleoyl-estrone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oleoyl-estrone.Approved
TorasemideOleoyl-estrone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Oleoyl-estrone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Oleoyl-estrone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Trichlorfon.Vet Approved
TrichlormethiazideOleoyl-estrone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Oleoyl-estrone.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Oleoyl-estrone.Approved
TromethamineThe bioavailability of Oleoyl-estrone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Oleoyl-estrone.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Zoster vaccine.Approved
VoriconazoleThe serum concentration of Oleoyl-estrone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinOleoyl-estrone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Oleoyl-estrone.Approved, Investigational
ZeranolThe serum concentration of Oleoyl-estrone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Oleoyl-estrone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Oleoyl-estrone.Withdrawn
Food Interactions
Not Available

References

General References
  1. Sanchis D, Balada F, del Mar Grasa M, Virgili J, Peinado J, Monserrat C, Fernandez-Lopez JA, Remesar X, Alemany M: Oleoyl-estrone induces the loss of body fat in rats. Int J Obes Relat Metab Disord. 1996 Jun;20(6):588-94. [PubMed:8782737]
  2. Salas A, Remesar X, Esteve M: Oleoyl-estrone treatment activates apoptotic mechanisms in white adipose tissue. Life Sci. 2007 Jan 2;80(4):293-8. Epub 2006 Sep 30. [PubMed:17055002]
External Links
PubChem Compound
6918373
PubChem Substance
175426878
ChemSpider
5293576
Wikipedia
Oleoyl-estrone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentAlzheimer's Disease (AD) / Psychosis1
2Unknown StatusTreatmentBMI >30 kg/m22

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.87e-06 mg/mLALOGPS
logP9.64ALOGPS
logP11.23ChemAxon
logS-8ALOGPS
pKa (Strongest Acidic)19.96ChemAxon
pKa (Strongest Basic)-7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.37 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity162.99 m3·mol-1ChemAxon
Polarizability67.63 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9709
Caco-2 permeable+0.7297
P-glycoprotein substrateSubstrate0.6692
P-glycoprotein inhibitor IInhibitor0.6415
P-glycoprotein inhibitor IIInhibitor0.5314
Renal organic cation transporterNon-inhibitor0.8248
CYP450 2C9 substrateNon-substrate0.7902
CYP450 2D6 substrateNon-substrate0.8958
CYP450 3A4 substrateSubstrate0.6873
CYP450 1A2 substrateNon-inhibitor0.8287
CYP450 2C9 inhibitorNon-inhibitor0.8072
CYP450 2D6 inhibitorNon-inhibitor0.9151
CYP450 2C19 inhibitorInhibitor0.5344
CYP450 3A4 inhibitorNon-inhibitor0.8284
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.542
Ames testNon AMES toxic0.9253
CarcinogenicityNon-carcinogens0.8829
BiodegradationNot ready biodegradable0.9891
Rat acute toxicity1.7534 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.876
hERG inhibition (predictor II)Non-inhibitor0.617
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Estrane steroids / 17-oxosteroids / Phenanthrenes and derivatives / Tetralins / Ketones / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Steroid ester / Estrane-skeleton / 17-oxosteroid / Oxosteroid / Phenanthrene / Tetralin / Benzenoid / Ketone / Carboxylic acid ester / Carboxylic acid derivative
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2007 04:27 / Updated on December 01, 2017 15:33